PMID- 30464377
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 12
DP  - 2018
TI  - Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life 
      treatment experiences.
PG  - 2177-2181
LID - 10.2147/OPTH.S178228 [doi]
AB  - PURPOSE: The purpose of this article was to study the real-life treatment results 
      of polypoidal choroidal vasculopathy (PCV). DESIGN: This was a retrospective 
      study. METHODS: Patients with presumed age-related macular degeneration were 
      reviewed, and PCV diagnosis was made using the EVEREST study criteria. Outcomes 
      were changes in visual acuity (VA) and central retinal thickness, time between 
      treatments, follow-up time, and number of treatments. RESULTS: The prevalence of 
      PCV was 30.8%. At the beginning, 195 eyes received monotherapy of anti-vascular 
      endothelial growth factor (anti-VEGF) injections, either bevacizumab or 
      ranibizumab, and only six eyes received the combination of anti-VEGF injection 
      and photodynamic therapy (PDT) at the time of the first treatment. During the 
      follow-up, some patients received "rescue or add-on" PDT when they had a poor 
      response after anti-VEGF injections. After 4 years, the average number of 
      injections was 8.25 and 9.15 for the anti-VEGF monotherapy and the combination 
      groups, respectively. The average time between the first anti-VEGF injections and 
      the first PDT was 21.4 months. The average VA in the anti-VEGF monotherapy group 
      increased by 1.5 letters, whereas it decreased by 0.95 letters in the combination 
      group (P=0.48). CONCLUSION: The review demonstrated the same visual outcomes 
      between the combination therapy of anti-VEGF injections and rescue or add-on PDT 
      vs monotherapy anti-VEGF injections in PCV treatment. When compared with EVEREST 
      II and Planet studies, the "initial" or "rescue or add-on PDT" might have 
      different effects on the final visual outcomes.
FAU - Ratanasukon, Mansing
AU  - Ratanasukon M
AD  - Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 
      Hat Yai, Songkhla Province 90110, Thailand, mratanasukon@yahoo.com.
FAU - Bhurayanontachai, Patama
AU  - Bhurayanontachai P
AD  - Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 
      Hat Yai, Songkhla Province 90110, Thailand, mratanasukon@yahoo.com.
FAU - Jirarattanasopa, Pichai
AU  - Jirarattanasopa P
AD  - Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, 
      Hat Yai, Songkhla Province 90110, Thailand, mratanasukon@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20181030
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC6214312
OTO - NOTNLM
OT  - anti-vascular endothelial growth factor
OT  - photodynamic therapy
OT  - polypoidal choroidal vasculopathy
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/11/23 06:00
MHDA- 2018/11/23 06:01
PMCR- 2018/10/30
CRDT- 2018/11/23 06:00
PHST- 2018/11/23 06:00 [entrez]
PHST- 2018/11/23 06:00 [pubmed]
PHST- 2018/11/23 06:01 [medline]
PHST- 2018/10/30 00:00 [pmc-release]
AID - opth-12-2177 [pii]
AID - 10.2147/OPTH.S178228 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2018 Oct 30;12:2177-2181. doi: 10.2147/OPTH.S178228. eCollection 
      2018.